Differential roles of PDGFR‐α and PDGFR‐β in angiogenesis and vessel stability

Preclinical and clinical evaluations of individual proangiogenic/arteriogenic factors for the treatment of ischemic myocardium and skeletal muscle have produced unfulfilled promises. The establishment of functional and stable arterial vascular networks may require combinations of different angiogenic and arte‐riogenic factors. Using in vivo angiogenesis and isch‐emic hind‐limb animal models, we have compared the angiogenic and therapeutic activities of fibroblast growth factor 2 (FGF‐2) in combinations with PDGF‐AA and PDGF‐AB, two members of the platelet‐derived growth factor (PDGF) family, with distinct receptor binding patterns. We show that both PDGF‐AA/FGF‐2 and PDGF‐AB/FGF‐2 in combinations synergistically induce angiogenesis in the mouse cornea. FGF‐2 up‐regulates PDGFR‐α and ‐β expression levels in the newly formed blood vessels. Interestingly, PDGF‐AB/ FGF‐2, but not PDGF‐AA/FGF‐2, is able to stabilize the newly formed vasculature by recruiting pericytes, and an anti‐PDGFR‐β neutralizing antibody significantly blocks PDGF‐AB/FGF‐2‐induced vessel stability. These findings demonstrate that PDGFR‐β receptor is essen‐tial for vascular stability. Similarly, PDGF‐AB/FGF‐2 significantly induces stable collateral growth in the rat ischemic hind limb. The high number of collaterals induced by PDGF‐AB/FGF‐2 leads to dramatic im‐provement of the paw's skin perfusion. Immunohisto‐chemical analysis of the treated skeletal muscles con‐firms that a combination of PDGF‐AB and FGF‐2 significantly induces arteriogenesis in the ischemic tis‐sue. A combination of PDGF‐AB and FGF‐2 would be optimal proangiogenic agents for the treatment of ischemic diseases.—Zhang, J., Cao, R., Zhang, Y., Jia, T., Cao, Y., Wahlberg, E. Differential roles of PDGFR‐α and PDGFR‐β in angiogenesis and vessel stability. FASEB J. 23, 153‐163 (2009)

[1]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[2]  E. Ritman,et al.  Vascular Endothelial Growth Factor Is Required for Coronary Collateral Growth in the Rat , 2005, Circulation.

[3]  J. Ware,et al.  Therapeutic angiogenesis in cardiovascular disease , 2003, Nature Reviews Drug Discovery.

[4]  E. Stone A very effective treatment for neovascular macular degeneration. , 2006, The New England journal of medicine.

[5]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[6]  J. Arbiser Why targeted therapy hasn't worked in advanced cancer. , 2007, The Journal of clinical investigation.

[7]  P. Carmeliet Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: a goal for therapeutic angiogenesis? , 2000, Circulation research.

[8]  J. Isner,et al.  Left Ventricular Electromechanical Mapping to Assess Efficacy of phVEGF165 Gene Transfer for Therapeutic Angiogenesis in Chronic Myocardial Ischemia , 2000, Circulation.

[9]  Yihai Cao,et al.  Angiogenesis inhibited by drinking tea , 1999, Nature.

[10]  S. Kumar,et al.  ANGIOGENESIS FACTOR FROM HUMAN MYOCARDIAL INFARCTS , 1983, The Lancet.

[11]  Philippe Soriano,et al.  Chimaeric analysis reveals role of Pdgf receptors in all muscle lineages , 1998, Nature Genetics.

[12]  H. Inui,et al.  Molecular structure and transcriptional regulation of the gene for the platelet-derived growth factor alpha receptor in cultured vascular smooth muscle cells. , 1995, The Journal of clinical investigation.

[13]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[14]  J. Fiddes,et al.  Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. , 1986, Science.

[15]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[16]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[17]  Yihai Cao,et al.  Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs , 2007, Proceedings of the National Academy of Sciences.

[18]  M. Larsen,et al.  Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. , 2006, Acta ophthalmologica Scandinavica.

[19]  David J. Mooney,et al.  Spatio–temporal VEGF and PDGF Delivery Patterns Blood Vessel Formation and Maturation , 2007, Pharmaceutical Research.

[20]  P. Carmeliet Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[21]  B R Johansson,et al.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.

[22]  M. Simons Angiogenesis: where do we stand now? , 2005, Circulation.